Navigation Links
AskBio's Perspective on Pfizer's 1b Clinical Trial Results on Duchenne MD Gene Therapy
Date:7/2/2019

Pfizer reported results from a Phase 1b clinical trial of PF-06939926, its investigational gene therapy for Duchenne Muscular Dystrophy (DMD). Affecting young boys almost exclusively, DMD is a rare genetic disease that causes progressive muscle weakness. Most patients typically lose the ability to walk by age 12 and die of cardiac or respiratory failure by their mid-20s.

Pfizer acquired the therapeutic platform to treat DMD when they purchased Bamboo Therapeutics from AskBio in 2016. It was one of many milestones that have been reached since AskBio was founded in 2001 on the groundbreaking gene therapy work of our co-founders, Dr. Jude Samulski and Dr. Xiao Xiao.

More importantly, Pfizer presented data that for the first time demonstrated striking improvement in North Star scores for patients of this age range that typically show steady functional decline. In addition, Pfizer presented safety data for each patient treated. This included side effects such as nausea, vomiting, reduced appetite, etc., observations commonly seen from all high-dose AAV treatments to date. Of particular note, one patient required hospitalization for IV anti-emetics for vomiting, while another at the two-week time point was asymptomatic but tested positive for “complementation activation” and acute kidney injury, an observation previously documented from Solid Biosciences’ DMD trial. All symptoms were clinically addressed, and Pfizer announced continued efforts to advance to Phase 3 pivotal studies worldwide.

We commend Pfizer, Solid, Sarepta Therapeutics and all other companies for their work in finding curative therapies for life-threatening diseases such as DMD. Seeing this through the eyes of the families, the gain of muscle functions in the Pfizer study in six- to 12-year-old patients provided real benefit in quality of life improvements and halting disease progression.

We congratulate Pfizer on the progress with a potentially curative therapy for DMD and companies like AveXis that recently gained FDA approval for Zolgensma® to treat Spinal Muscular Atrophy. The research that companies like Pfizer and AveXis are doing based on the adeno-associated virus (AAV) technology originally developed by Dr. Samulski and Dr. Xiao is the foundation used by more than two-thirds of the gene therapy industry worldwide.

Patient safety is and must remain the most important concern in clinical studies, and while there may be some adverse effects in early stage trials for new gene therapies, we are all working to minimize those instances. We should all celebrate the accomplishments that bring us closer to finding cures for the millions of patients in need. To that end, it is important to recognize the truly innovative AAV discoveries made by Dr. Samulski and Dr. Xiao over the past three decades that have made potential treatments and other AAV therapies possible.

Dr. Samulski’s discovery of how the AAV could be safely used to deliver corrected genes to cells with genetic defects propelled one of the most exciting and inspiring fields in medical research today, now the foundation for an entire industry.

Dr. Xiao Xiao was the first to create a mini-dystrophin gene that opened the door for the development of potential DMD therapies.

Dr. Josh Grieger, AskBio’s Chief Technology Officer, pioneered the Pro10 producer cell line that is now paving the way for increasing the efficiency of developing and producing potentially curative therapies to reach all patients.

AskBio is on the forefront of the gene therapy industry with an extensive gene therapy platform that includes a pipeline of clinical stage therapeutics, streamlined manufacturing processes, an extensive capsid library and a rich portfolio of AAV-related intellectual property. The company’s commitment to bring effective therapies to market is only rivaled by its commitment to reduce the cost of production and increase access with new innovative technology such as Doggybone DNA, thin-film technology and other AAV development processes.

About AskBio

Asklepios BioPharmaceutical, Inc. (AskBio) is a privately held, clinical stage gene therapy platform company dedicated to improving the lives of children and adults with rare genetic disorders. AskBio’s gene therapy platform includes an industry-leading proprietary cell line manufacturing process known as Pro10™ and an extensive AAV capsid library. The company has generated hundreds of proprietary third generation gene vectors, several of which that have entered clinical testing, and maintains a portfolio of clinical programs across a range of indications including Pompe, Limb Girdle Muscular Dystrophy, Cystic Fibrosis, Myotonic Muscular Dystrophy, Huntington’s, Hemophilia (Chatham Therapeutic/Takeda) and Duchenne Muscular Dystrophy (Bamboo Therapeutics/Pfizer). For more information, visit http://www.askbio.com.

Read the full story at https://www.prweb.com/releases/askbio_s_perspective_on_pfizer_s_1b_clinical_trial_results_on_duchenne_md_gene_therapy/prweb16418224.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Survey of Participants from Landmark GRACE Trial Provides Patients Perspectives from an HIV Clinical Study
2. Narcolepsy Patient Community Prepares to Share Life Impacts, Treatment Perspectives with FDA Regulators
3. The Corporate Reputation of Pharma in 2012: The Patient Perspective on 29 of the Worlds Leading Pharma Companies
4. CPhI Panel to Analyse New Industry Perspectives and Innovations Ahead of Predictive 2014 Annual Report
5. Alzheimers Reviewed by NeuroPerspective
6. Pharmaceutical Industry Making Adjustments to Include Patient Perspective across Medical and Commercial Operations
7. Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition
8. The Corporate Reputation of Pharma - The Global Patient Perspective in 2014
9. Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries
10. Corporate Reputation of Pharma in 2014 - A Perspective of Cancer Patient Groups
11. Ebola--Threat, Challenge, and Response: A PPE Perspective : Ebola Containment and Preparedness has Spurred a Small Boost to the PPE Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2019)... ... August 19, 2019 , ... Like so many senior executives in complex industries, a former Procter ... to be able to talk about it. He turned a make-it-or-break-it opportunity — debating ... all types of speaking events. , On Monday, September 9, 2019 at 12pm EDT ...
(Date:8/19/2019)... MIAMI (PRWEB) , ... August 18, 2019 , ... Laurence ... of all ages across the globe. His work spans genres and generations. On television, ... Scenes,” a series that covers topics important to today's world and gives viewers information ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... process to promote standards of excellence within the field of treatment for eating ... growth and communication with others who have a similar mission. , Founded ...
Breaking Medicine Technology:
(Date:8/15/2019)... (PRWEB) , ... August 15, 2019 , ... ... assistance to pathology residents who have been directly affected by the closure of ... support of donations gathered during the campaign, the ASCP Foundation will be making ...
(Date:8/14/2019)... ... 14, 2019 , ... Teguar Corporation has claimed the #3719 position on the ... established as a mark of success for some of Americas top companies and has ... list in 2015, 2016 and 2017. This year, Teguar secured a spot on the ...
(Date:8/14/2019)... ... August 13, 2019 , ... New Hampshire-based Vera ... resveratrol, today announced an expansion of its line of CBD-infused coffees with the release ... CBD in a 12-oz bag. , “We are excited to expand our CBD-infused ...
(Date:8/14/2019)... ... ... While it is commonly understood that good nutrition promotes general health, consumers are ... and, in some cases, reverse certain medical conditions, according to health and wellness research ... trying to manage a health or medical condition by making healthy food and beverage ...
(Date:8/12/2019)... ... ... Parents craving a nutritious and delicious snack for their kids have a new ... need. IsaKids® Super Smoothie is one of three products launched yesterday at Isagenix ... company also debuted Organic Greens, an updated version of its Isagenix Greens™, and a ...
Breaking Medicine News(10 mins):